211 related articles for article (PubMed ID: 23613147)
1. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.
Rosalia RA; Silva AL; Camps M; Allam A; Jiskoot W; van der Burg SH; Ossendorp F; Oostendorp J
Cancer Immunol Immunother; 2013 Jul; 62(7):1161-73. PubMed ID: 23613147
[TBL] [Abstract][Full Text] [Related]
2. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming.
Zupančič E; Curato C; Paisana M; Rodrigues C; Porat Z; Viana AS; Afonso CAM; Pinto J; Gaspar R; Moreira JN; Satchi-Fainaro R; Jung S; Florindo HF
J Control Release; 2017 Jul; 258():182-195. PubMed ID: 28511928
[TBL] [Abstract][Full Text] [Related]
3. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
[TBL] [Abstract][Full Text] [Related]
4. Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.
Hanlon DJ; Aldo PB; Devine L; Alvero AB; Engberg AK; Edelson R; Mor G
Am J Reprod Immunol; 2011 Jun; 65(6):597-609. PubMed ID: 21241402
[TBL] [Abstract][Full Text] [Related]
5. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
Ramadan G
Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
[TBL] [Abstract][Full Text] [Related]
7. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
[TBL] [Abstract][Full Text] [Related]
8. CD69 does not affect the extent of T cell priming.
Alari-Pahissa E; Notario L; Lorente E; Vega-Ramos J; Justel A; López D; Villadangos JA; Lauzurica P
PLoS One; 2012; 7(10):e48593. PubMed ID: 23119065
[TBL] [Abstract][Full Text] [Related]
9. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles.
Hamdy S; Haddadi A; Shayeganpour A; Samuel J; Lavasanifar A
Pharm Res; 2011 Sep; 28(9):2288-301. PubMed ID: 21560020
[TBL] [Abstract][Full Text] [Related]
10. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4
Tang XD; Lü KL; Yu J; Du HJ; Fan CQ; Chen L
Cancer Immunol Immunother; 2022 Dec; 71(12):2969-2983. PubMed ID: 35546204
[TBL] [Abstract][Full Text] [Related]
12. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
13. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD
Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913
[TBL] [Abstract][Full Text] [Related]
14. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
15. Poly Lactic-co-Glycolic Acid Nanoparticles Containing Human Gastric Tumor Lysates as Antigen Delivery Vehicles for Dendritic Cell-Based Antitumor Immunotherapy.
Kohnepoushi C; Nejati V; Delirezh N; Biparva P
Immunol Invest; 2019 Nov; 48(8):794-808. PubMed ID: 31094258
[TBL] [Abstract][Full Text] [Related]
16. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.
Fan K; Borden E; Yi T
J Interferon Cytokine Res; 2009 Aug; 29(8):451-60. PubMed ID: 19514839
[TBL] [Abstract][Full Text] [Related]
18. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
19. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery.
Zhang Z; Tongchusak S; Mizukami Y; Kang YJ; Ioji T; Touma M; Reinhold B; Keskin DB; Reinherz EL; Sasada T
Biomaterials; 2011 May; 32(14):3666-78. PubMed ID: 21345488
[TBL] [Abstract][Full Text] [Related]
20. Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.
Pato A; Eisenberg G; Machlenkin A; Margalit A; Cafri G; Frankenburg S; Merims S; Peretz T; Lotem M; Gross G
Clin Exp Immunol; 2015 Nov; 182(2):220-9. PubMed ID: 26212048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]